InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.61
(
1.15%
)
US TECH 100
19,202.80
(
1.10%
)
Dow Jones
41,175.08
(
1.14%
)
Brent Oil
78.38
(
0.00%
)
Bitcoin
63,907.54
(
-0.41%
)
Post# of 160314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

garthmd08

Send PM Follow Ignore
Followers 0
Posts 218
Boards Moderated 0
Alias Born 07/25/2008

garthmd08

Re: None

Wednesday, 05/26/2010 12:32:40 PM

Wednesday, May 26, 2010 12:32:40 PM

Post# of 160314
CRXX--This is from May 3, but I'd missed and don't know if it was posted here.

CombinatoRx Inc. /quotes/comstock/15*!crxx/quotes/nls/crxx (CRXX 1.50, +0.06, +4.17%) received FDA approval for Exalgo, a powerful once-a-day painkiller, on March 2. They have already partnered with Mallinckrodt, a subsidiary of Covidien PLC /quotes/comstock/13*!cov/quotes/nls/cov (COV 42.41, +0.66, +1.58%) , to distribute the drug in North America. Mallinckrodt will start shipping any day. CombinatoRx will be collecting substantial royalties, on top of the $40 million milestone payment they already received from Covidien. The royalty flow will move the stock up. Moreover, I think it is highly likely that Covidien will acquire CombinatoRx by the end of 2011, at a substantial multiple of the current price.

http://www.marketwatch.com/story/three-biotech-picks-for-may-2010-05-03?siteid=yhoof
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up